KHOS-NP
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
KHOS-NP |
Humane Osteosarkom Zell-Linie |
300235 |
cryovial |
265,00 |
KHOS-NP |
Humane Osteosarkom Zell-Linie |
330235 |
vital |
335,00 |
| Designation: | KHOS-NP |
| Depositor: | Rhim |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Age/Stage: | 13 years old |
| Gender: | female |
| Tissue: | Bone |
| Celltype: | osteosarcoma |
| Growth Properties: | monolayer |
| Description: | This cell line was derived from the HOS cell line (TE-85) by transformation using Kirsten murine sarcoma virus (Ki-MSV). The cells exhibit a high saturation density, a high plating efficiency in soft agar and produce tumors in nude mice. The cells are useful producing MSV pseudotypes with various ecotropic and xenotropic murine leukemia viruses. Cells carry the Ki-MSV genome but do not produce infectious virus particles or viral antigens. |
| Culture Medium: | Minimum essential medium (Eagle) in Earle's BSS supplemented with non-essential amino acids, L-glutamine and 10% fetal bovine serum. |
| Subculturing: | Remove medium, add fresh 0.025% trypsin solution for 2 to 3 minutes, remove trypsin and let the culture sit at room temperature until the cells detach. Add fresh medium, aspirate and dispense into new flasks. |
| Split Ratio: | A ratio of 1:2 to 1:4 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice |
References: Rhim JS et al. Non-producer human cells induced by murine sarcoma virus. Int J Cancer 15: 23-9, 1975. Rhim JS et al. Characterization of non-producer human cells induced by Kirsten sarcoma virus. Int J Cancer 16: 840-9, 1975. Ganjavi H et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 13: 415-9, 2006. Izbicka E et al. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models. Anticancer Res 26: 1983-8, 2006. | |
